The primary reason that people die from cancer is the development of metastatic disease. My laboratory primarily investigates the underlying genomic, transcriptomic, and signal transduction mechanisms involved in metastasis. As a surgeon-scientist who cares for people with lung, esophageal, and mesothelioma malignancies, I focus my laboratory’s studies on these specific cancers. We have focused a class of genes known as metastasis suppressor genes and, in particular, breast cancer metastasis suppressor I (BRMS1). BRMS1 is a 246aa protein mapped to chromosome 11q13, which functions as a metastases suppressor and has been shown to have functional relevance in breast cancer, melanoma, and lung cancer, among other solid tumors. We have identified important molecular functions of BRMS1 as a transcriptional repressor, an E3 ligase, and a mediator of RelA/p65 transcription in lung cancer in vivo and in vivo models, as well as in mouse models of metastases. We are also studying genomic predictors of recurrence and metastases in lung cancer, RNA editing and the resulting biology, and the development of a circulating tumor cell program. Our lab is fortunate to have access to human cancer tissue with matched normal tissue, which makes many of our patient-derived cancer discovery and validation models feasible.
David R. Jones, MD
Fiona and Stanley Druckenmiller Chair for Lung Cancer Research
Research FocusPhysician-scientist David R. Jones studies molecular mechanisms governing the development of metastases in lung and esophageal cancers.
- Patient-Derived Lung Adenocarcinoma Organoids (PDO) Program
- BRMS1-Mediated Suppression of Metastases in p53 Mutant Lung Adenocarcinoma
- Characterizing the role of the adenosine deaminase acting on RNA (ADAR) gene as a potential oncogene in lung cancer
- Tumor Genomics and Their Application in Early-Stage Lung Cancer
- Szymura SJ, Zaemes JP, Allison DF, Clift SH, D’Innocenzi JM, Gray LG, Mckenna BD, morris BB, Bekiranov S, LeGallo RD, Jones DR, Mayo MW. NF-ĸB upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small clell lung cancer. Cell Commun Signal 2019;17(1):24.
- Forde PM, Chaft JE, Smith KN, Anagnostou V, TCottrell TR, Hellmann MD, Yang SC, Jones DR, Broderick SR, Battafarano R, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Caushi J, Chan HY, Scharpf RB, White J, Gabrielson E, Zahurak M, Rosner G, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976-86.
- AACR Career Development Award for Translational Research in Lung Cancer 2001
- Member, Tumor Progression and Metastases Study Section NCI; 2010-16 (Chair 2014-16)
- Co-Director, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, MSKCC
- Castle Connolly Top Doctors for Cancer 2010-present